On May 15, 2024 Rondo Therapeutics, a biopharmaceutical company pioneering next-generation bispecific antibodies, reported oral presentations at both Protein & Antibody Engineering Summit (PEGS) and Antibody Engineering & Therapeutics (AET) EU (Press release, Rondo Therapeutics, MAY 15, 2024, View Source [SID1234643376]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Rondo Therapeutics will describe its immune-cell engaging bispecific antibody platforms and how it is building a clinical pipeline with a focus on treating solid tumors. The company will provide an update on its lead program, RNDO-564, a co-stimulatory T-cell engaging bispecific antibody targeting CD28 and Nectin-4 for the treatment of bladder cancer.
"Presenting our data at PEGS and AET EU represents a significant milestone for our company. This is a golden age for bispecific antibodies and we are delighted to be driving innovation in the field. Targeted signaling through the CD28 pathway is showing a lot of promise as an effective strategy for overcoming the challenges presented by solid tumors. We look forward to sharing our unique approach and commitment to developing novel immunotherapy options for patients with solid tumors," said Shelley Force Aldred, co-founder, and CEO of Rondo Therapeutics.
Presentation Details
Protein & Antibody Engineering Society (Boston, MA)
Date: Wednesday, May 15
Title: Bispecific Antibody Combination Strategies for Treating Solid Tumors
Presenter: Nathan D. Trinklein, PhD, Co-Founder and President, Rondo Therapeutics
Conference Link: https://www.pegsummit.com/
Antibody Engineering & Therapeutics EU (London, UK)
Date: Tuesday, June 5
Title: Co-stimulatory Bispecific Antibody Strategies for Treating Solid Tumors
Presenter: Starlynn Clarke, PhD, Director of Preclinical Biology, Rondo Therapeutics
Conference Link: https://informaconnect.com/antibody-engineering-europe/